FDA Approves First RAS-Targeted Pill for Metastatic Pancreatic Cancer

The drug is daraxonrasib, sold under the brand name RASONQUE™, an oral RAS(ON) inhibitor developed by Revolution Medicines⁠3⁠4⁠6⁠7⁠9⁠11. The FDA approved it for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy⁠3⁠4⁠6⁠7⁠9⁠11. In plain terms, it is for people whose cancer has spread and who have already been through standard drug treatment, or who cannot safely take the harsh multi-drug combinations that are otherwise the default⁠4⁠7. That is a population with almost nowhere left to turn⁠5⁠6⁠7.

What makes the approval historic is not just that it is a pill, but what the pill goes after⁠5⁠6. The drug targets the mutated RAS protein that drives tumor growth in more than 90% of pancreatic cancer cases⁠3⁠7. RAS is the central growth switch gone wrong in this disease, the mutation found in the overwhelming majority of tumors⁠3⁠7. The approval makes daraxonrasib the first RAS-targeted therapy for metastatic pancreatic cancer⁠9⁠11. It is described in coverage as first-of-a-kind and as a landmark for a previously intractable disease⁠5⁠6.

The FDA decision rests primarily on the pivotal randomized phase 3 RASolute 302 trial⁠9⁠11. The landmark clinical trial was led by Dana-Farber Cancer Institute⁠11. Randomization and phase 3 status matter here: this was not an early safety study or a single-arm signal, but a comparative test designed to show whether the new drug actually extends life against a control⁠9⁠11. USA Today reported that the trial showed life expectancy nearly doubled⁠4. The available excerpts do not publish the full survival curves, median months, hazard ratios, patient counts, or discontinuation rates, so the precise size of the benefit cannot be stated from this reporting file beyond that nearly-doubled description⁠4⁠9⁠11.

To understand why oncologists are calling this a sweeping advance for a disease that has few treatment options⁠7, it helps to understand what RAS has meant in pancreatic cancer. For a generation, RAS was the textbook example of an important but undruggable target, a protein too smooth and too essential to block without poisoning normal cells. The new drug is an oral RAS(ON) inhibitor, meaning it is designed to latch onto the switched-on, cancer-driving form of the protein⁠3⁠4⁠6⁠7⁠9⁠11. The success of that approach in a randomized phase 3 trial is why Scientific American framed the approval as heralding a new era for an intractable disease⁠5, and why ABC News framed it as a landmark drug shown to improve survival⁠6.

Speed is the other tell. Reuters described Revolution Medicines as winning speedy FDA approval⁠2, while CBS News described the decision as expedited⁠3. Expedited does not mean casual; it means regulators judged the need urgent enough to move faster than usual⁠2⁠3. For metastatic pancreatic adenocarcinoma after prior systemic therapy, there has been no targeted standard to fall back on, only different versions of chemotherapy that many patients cannot tolerate or have already exhausted⁠4⁠7. A once-daily pill for people who have received prior treatment or cannot receive combination chemotherapy directly answers that gap⁠4.

What is settled is the regulatory fact and the population. As of August 26, 2026, adults in the United States with metastatic pancreatic adenocarcinoma who meet the prior-therapy or ineligibility criteria have an FDA-approved RAS-directed oral option where none existed before⁠3⁠4⁠6⁠7⁠9⁠11. What is not settled in the material available here is almost everything a patient would ask next. The excerpts confirm nearly doubled life expectancy⁠4 but do not provide verified median survival times, risk-reduction percentages, or subgroup results. They identify RASolute 302 as the pivotal randomized phase 3 basis⁠9⁠11 and Dana-Farber as the trial leader⁠11, but they do not provide enrollment numbers, control-arm details, or follow-up duration.

There are larger blanks, too. No source in this file gives a list price or an annual cost figure. No source details insurance coverage, copay assistance, Medicare rules, or out-of-pocket caps. No source in this file provides the full label language on side effects, warnings, dose interruptions, or discontinuation rates. No source confirms specific regulatory designations or how many months ahead of schedule any action came, beyond the general characterization of expedited and speedy review⁠2⁠3. Those are not minor footnotes; for a once-daily cancer pill taken over months, tolerability and access determine whether a survival signal in a trial becomes survival in the real world. The honest answer from this reporting file is that the science crossed the FDA bar, while the practical picture remains to be filled in from the full label, the full trial publication, and the payer documents.

The temptation will be to declare victory and move on. That would misread both the biology and the history. Pancreatic cancer earned its reputation because early wins faded, because metastatic disease outsmarts single pathways, and because patients who need new drugs most are often the least able to tolerate them⁠5⁠6⁠7. Daraxonrasib now has to prove durability: how long responses last, who benefits most within that more-than-90% RAS-mutated majority⁠3⁠7, how it sequences with prior systemic therapy and with multiagent therapy for those who can still take it⁠4⁠7, and whether Dana-Farber-led results in RASolute 302 hold across broader clinics and older, sicker patients⁠11. None of those answers are in the approval headline, and all of them will decide what August 26 actually meant.

For now, the record supports a narrow but profound claim. After decades without a targeted option, people with metastatic pancreatic adenocarcinoma after prior therapy have one⁠3⁠4⁠6⁠7⁠9⁠11. It is a pill, taken once a day, aimed at the mutation that defines their disease⁠4⁠3⁠7. It moved through the FDA quickly because the need was judged urgent⁠2⁠3. And in the trial that won approval, people lived nearly twice as long⁠4. Against a five-year survival rate of just 13%⁠7, that is why patient advocates call it a sweeping advance for a disease that has few treatment options⁠7 — and why the next documents to demand are not press releases, but data.